



Published in final edited form as:

Science. 2014 August 1; 345(6196): 573–577. doi:10.1126/science.1254517.

Helminth Infection Reactivates Latent γ -herpesvirus Via Cytokine Competition at a Viral Promoter

T.A. Reese¹, B.S. Wakeman², H.S. Choi^{3,#}, M.M. Hufford^{4,#}, S.C. Huang¹, X. Zhang¹, M.D. Buck¹, A. Jezewski¹, A. Kambal¹, C.Y. Liu¹, G. Goel⁵, P.J. Murray⁶, R.J. Xavier^{5,&}, M.H. Kaplan^{4,&}, R. Renne^{3,&}, S.H. Speck^{2,&}, M.N. Artyomov¹, E.J. Pearce¹, and H.W. Virgin^{1,*}

¹Department of Pathology and Immunology, Washington University School of Medicine, St. Louis MO

²Emory University Vaccine Center, Atlanta, GA

³Department of Molecular Genetics and Microbiology, University of Florida, Gainesville, FL

⁴Departments of Pediatrics and Microbiology and Immunology, Indiana University School of Medicine, Indianapolis, IN 46202

⁵Center for Computational and Integrative Biology and Gastrointestinal Unit, Massachusetts General Hospital, Harvard Medical School, Boston, MA

⁶Departments of Infectious Diseases and Immunology, St. Jude Children's Research Hospital, Memphis, TN

Abstract

Mammals are co-infected by multiple pathogens that interact through unknown mechanisms. We found that helminth infection, characterized by the induction of the cytokine interleukin-4 (IL-4) and the activation of the transcription factor Stat6, reactivated murine gammaherpesvirus infection *in vivo*. IL-4 promoted viral replication and blocked the antiviral effects of interferon- γ (IFN γ) by inducing Stat6 binding to the promoter for an important viral transcriptional transactivator. IL-4 also reactivated human Kaposi's sarcoma associated herpesvirus from latency in cultured cells. Exogenous IL-4 plus blockade of IFN γ reactivated latent murine gammaherpesvirus infection *in vivo*, suggesting a 'two-signal' model for viral reactivation. Thus chronic herpesvirus infection, a

*Correspondence to: virgin@wustl.edu.

#These authors contributed equally

&These authors contributed equally

TAR designed the project, performed experiments, and wrote the paper. HWV assisted with project design and paper writing. BSW and SHS defined promoters and performed promoter assays. XZ created and characterized MHV68-cre virus, performed LD-PCR and western blots. HSC and RR performed KSHV experiments. MMH and MHK performed ChIP experiments. SCH and EJP helped design helminth experiments and supplied reagents. MDB did RT-PCR for gene 50 and host genes. AJ did flow cytometry with IL-4 in RAW264.7 cells. AK did western blots. CYL did plaque assays. GG and RX did initial bioinformatic analysis of gene expression by array, later replaced with RNASeq. PJM provided arginase mice. MNA analyzed sequencing data.

Supplementary Materials:

Materials and Methods

Figures S1–S9

Tables S1

References (32–52)

component of the mammalian virome, is regulated by the counterpoised actions of multiple cytokines on viral promoters that have evolved to sense host immune status.

Mammals are populated by many chronic viruses, termed the virome, which can regulate host physiology and disease susceptibility(1). For example, more than 90% of humans are latently infected with herpesviruses that, after clearance of acute infection, produce little infectious virus and often cause no overt disease. Like human gammaherpesviruses Epstein Barr Virus (EBV) and Kaposi's sarcoma associated herpesvirus (KSHV), murine gammaherpesvirus-68 (MHV68) establishes lifelong latency. Studies in this model system showed that the cytokine IFN γ inhibits MHV68 replication and reactivation from macrophages, a major cellular site for latency(2–5), controls persistent replication *in vivo*(6), and is present at low amounts during latency(7).

Many people around the world are co-infected with herpesviruses and intestinal helminths. While herpesviruses can modulate immunity to harm or benefit the host(7–11), the effects of helminth co-infection on chronic herpesvirus infection are unexplored. Intestinal helminths generate strong T helper 2 (Th2)-driven cytokine responses, which counter the biological effects of IFN γ , and drive the activation of macrophages with an M2 (immunoregulatory) rather than an M1 (pro-inflammatory) phenotype(12). Parasitic worms may influence control of pathogens, including *Mycobacterium tuberculosis*, HIV, and *Plasmodium* species in humans, but there are few studies elucidating the mechanisms behind this immunomodulation(13). Thus, we considered the hypothesis that parasite infection would induce MHV68 reactivation *in vivo*.

We examined the effects of acute infection with *Heligmosomoides polygyrus* or *Schistosomiasis mansoni* (*Sm*) egg administration on MHV68 reactivation from latency using a MHV68 virus expressing luciferase under the control of a lytic viral promoter upon reactivation from latency *in vivo* (MHV68-M3-FL)(14). Both acute *H. polygyrus* infection and *Sm* egg challenge reactivated MHV68 infection (Fig. 1A–D). Mice latently infected for over 100 days also showed increased luciferase expression following *Sm* egg challenge (fig. S1). By contrast, infection with the systemic bacteria, *Listeria monocytogenes*, did not stimulate viral reactivation (fig. S2). Thus, responses to either a nematode parasite or trematode eggs induced herpesvirus reactivation, suggesting a role for Th2 cytokines in viral reactivation.

To determine whether Th2 cytokines affect latently infected macrophages we compared host gene expression patterns in virally infected and uninfected macrophages during chronic infection. We engineered MHV68 to express cre-recombinase (MHV68-cre) from a locus permitting heterologous gene expression without altering viral replication or reactivation(15) (fig. S3). Reporter mice in which fluorescent protein expression is induced by cre recombination (Rosa26-floxed stop-eYFP or tandem dimer (td)RFP(16)) were infected with MHV68-cre. Virus-positive and virus-negative cells sorted from latently infected mice (fig. S3G) were subjected to RNAseq analysis. Transcription in these cells was compared to that in bone marrow-derived macrophages (BMDMs) stimulated with IL-4 (M2) or IFN γ plus lipopolysaccharide (LPS) (M1), compared to untreated BMDMs (M0). Gene set enrichment analysis (GSEA) revealed that genes upregulated in M1 BMDMs were enriched in virus-

positive macrophages whereas genes upregulated in M2 BMDMs were enriched in virus-negative cells (Fig. 2A, and table S1). This was consistent with the role of IFN γ , which drives M1 macrophage polarization, in inhibiting MHV68 replication and reactivation(3, 4). We therefore tested whether latent MHV68 infection was restricted to M1-type macrophages by infecting tandem dimer (td)RFP mice carrying the Arginase-1 (*Arg1*)-YFP reporter (YARG, a marker for macrophages stimulated with Th2 cytokines)(17) with MHV68-cre. Surprisingly, virus-positive macrophages were either *Arg1*-negative or *Arg1*-positive (Fig. 2B, C), suggesting that, despite the role for IFN γ in controlling chronic MHV68 infection, at least some virus-infected cells were exposed to cytokines that drive *Arg-1* expression *in vivo*.

The presence of an IL-4 signature in some virus-infected macrophages along with the observation that Th2 cytokine-inducing parasites promoted reactivation from latency, suggested a role for IL-4 in viral infection. We tested this by determining the effect of IL-4 on MHV68 replication in BMDMs. Treatment with IL-4 increased *Arg1* expression (fig. S4A) consistent with M2 polarization(18). As expected, few infected BMDMs expressed lytic viral antigens upon MHV68 infection(19). However, IL-4 pretreatment increased the number of BMDMs expressing viral proteins and enhanced viral replication (Fig. 3A, fig. S4B–D), and increased infection of transformed RAW264.7 macrophages (fig. S4E). Treatment with IL-4 after MHV68 infection increased viral replication (fig. S4F), indicating that IL-4 acts on replication rather than by increasing the number of infected cells. Enhancement of replication was dependent on the Th2-associated transcription factor Stat6 (Fig. 3A), and occurred with IL-13 stimulation, another Th2-associated cytokine that utilizes the IL-4 receptor α chain and signals via Stat6 (Fig. 3B, fig. S4D, G). The Th2 cytokine IL-5, which does not signal through Stat6, did not promote MHV68 replication (Fig. 3B).

After treatment with IL-4, the majority of infected cells did not express the M2 markers CD206 or *Arg1* (Fig. 3A, and fig. S4A), suggesting that not all IL-4-induced changes in macrophage differentiation are required for enhanced MHV68 replication(20). Etomoxir blocks IL-4-induced changes in fatty-acid oxidation(21) and upregulation of CD206 (fig. S5A) but did not block enhancement of MHV68 replication by IL-4 (fig. S5B). Moreover, IL-4 enhanced replication in the absence of PPAR γ or ARG1, key proteins involved in M2 macrophage function, or iNOS, an essential protein in M1 macrophage function (fig. S5C–G)(20). Importantly, IL-4 antagonized IFN γ -mediated suppression of viral replication (Fig. 3C)(3). Because Stat6 antagonizes Stat1(22), we tested whether IL-4 promoted virus replication in the absence of Stat1. IL-4 increased virus replication in Stat1-deficient BMDMs (fig. S6).

Previously, we found that IFN γ -mediated suppression of viral replication was associated with inhibition of promoters driving expression of the essential viral latent-to-lytic switch gene (*gene 50*) (3, 23). Importantly, IL-4 antagonizes IFN γ -mediated suppression of *gene 50* transcription (Fig. 3D). This effect was specific to the viral promoter because IL-4 did not block IFN γ -mediated induction of *Nos2*, and IFN γ did not inhibit IL-4-mediated induction of *Arg1* and *Relma/Fizz1* (fig S7). Furthermore, IL-4 and IL-13 transactivated the *gene 50* N4/N5 promoter (Fig. 3E)(24), and IL-4 antagonized IFN γ -mediated suppression of N4/N5 promoter (Fig. 3F). The effect of IL-4 on the N4/N5 promoter was diminished by mutation

of two of four putative Stat-binding sites in the promoter (Fig. 3G, fig. S8). Further, chromatin immunoprecipitation experiments revealed that Stat6 bound to the N4/N5 promoter after IL-4 treatment of MHV68-infected cells (Fig. 3H). Taken together, these data suggest that activated Stat6 induced by IL-4/IL-13 promotes viral replication by binding to and acting on a viral promoter to induce expression of *gene 50*.

These counterbalancing effects of IFN γ and IL-4 on virus replication and viral promoter activity suggested a potential mechanism by which IL-4-inducing pathogens such as helminths promote reactivation. We therefore treated mice infected with MHV68-M3-FL virus with a blocking antibody to IFN γ (clone H22)(25), an isotype control antibody (clone PIP), long-lasting IL-4 complexes (IL4c)(26), or a combination of anti IFN γ and IL4c. No reactivation was observed after treatment with anti-IFN γ , IL4c, or PIP alone, indicating that a single signal was insufficient to reactivate virus *in vivo*. However, robust reactivation was observed in mice that received a combination of IL-4c and anti-IFN γ (Fig. 4A, B, fig. S9A). We next assayed reactivation using an independent assay(27, 28). Little or no preformed virus was detectable in tissues after treatment with PIP, IL4c, or anti-IFN γ alone(27), while treatment with IL-4c plus anti-IFN γ increased infectious virus (fig. S9B, C). Together these data supports a 'two-signal' mechanism by which co-infections could induce reactivation via induction of IL-4 and inhibition of Th1 responses(12).

Increased reactivation after treatment with both IL4c/anti-IFN γ required Stat6 (Fig. 4C). We did not test the role of Stat1 or the IFN γ receptor because both are required to establish latency(6). To assess whether the effects of helminth infection on MHV68 reactivation also required Stat6, we challenged MHV68-infected Stat6KO mice with *H. polygyrus*. We found that helminth infection did not reactivate MHV68 from latency in Stat6KO mice, further supporting a two-signal model for control of gammaherpesvirus reactivation *in vivo* (Fig. 4D).

Our results suggested a possible role for IL-4 in human gammaherpesvirus reactivation. We therefore tested whether IL-4 could reactivate the human gammaherpesvirus, KSHV in the BCBL-1 human B cell lymphoma cell line. We found that treatment with IL-4 increased immediate early (RTA, ORF45, and ORF57) and late viral transcripts (ORF19) (29)(Fig. 4E). RTA is the homolog in KSHV of MHV68 *gene50*, and ORF 45 and ORF57 are both transactivators, indicating a common role of IL-4 in regulating important viral transcriptional transactivators. Furthermore, IL-4 treatment of cells increased virus production (Fig. 4F), indicating that IL-4 is capable of inducing reactivation of KSHV.

A remarkable aspect of herpesvirus infection is its permanence despite ongoing immunity combined with the capacity to reactivate and spread to new hosts. This work illuminates one potential mechanism by which a gammaherpesvirus exhibits these two apparently disparate functions. Our data suggest that the virus evolved cytokine-responsive promoters to remain latent under some conditions (IFN γ -dominant) while reactivating under other conditions (IL-4-dominant). In this setting, co-infection may govern the outcome of reactivation by changing the balance in IL-4 and IFN γ , thus raising a potential issue with herpesvirus reactivation and proposed live helminth therapies(12). Additionally, our data illustrate one potential mechanism by which helminths and other Type 2 immune response-inducing

parasites influence host control of another pathogen through M2 macrophage polarization(13). The fact that viral promoters for an essential gene are responsive to host cytokines implies that the viral genome evolved to sense the infection status of the host. We speculate that a similar mechanism for IL-4-induced reactivation of KSHV could also be true. Although not extensively studied, seroprevalence to KSHV is associated with hookworm and other parasitic infections in Uganda(30). Intriguingly, certain Burkitt's lymphoma cell lines are reported to express EBV transcripts in response to IL-4(31).

Although mouse studies are done in specific pathogen-free animals, our data suggest that there is added complexity when multiple pathogens infect the same host, particularly in situations where one pathogen has the capacity to respond to specific immune signals generated to another pathogen to regulate chronic infection. Previously we showed that herpesvirus infection, a component of the mammalian virome(1) enhances resistance to some pathogens(7). Here we demonstrate the opposite effect, that co-infection regulates herpesvirus reactivation. These studies emphasize that immunity to chronic infection is a dynamic equilibrium regulated by co-infections, in part through highly evolved pathogen genomes with the capacity to sense host cytokines.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

TAR was supported by Damon Runyon Postdoctoral Fellowship. This work was supported by grant U54 AI057160 and RO1 CA96511 to HWV, and grant AI032573 to EJP. The authors would like to thank R. Schreiber and K. Sheehan for supplying anti-IFN γ and PIP; G.Randolph and E. Gautier for PPAR γ *f/f*×LyzMcre mice and helpful discussion; J. Urban for help setting up the *H. polygyrus* system; D. Kreamalmeyer for animal care and breeding; members of the Virgin lab for manuscript review and discussion; the Genome Technology Access Center at Washington University for sequencing; and the Flow Cytometry Core at Washington University for assistance with sorting. The data presented in this manuscript are tabulated in the main paper and in the supplementary materials. The accession number for RNAseq data on virus-infected cells is GSE58116, and the accession number for the BMDMs is GSE21895.

References and Notes

1. Virgin HW. The Virome in Mammalian Physiology and Disease. *Cell*. 2014; 157:142–150. [PubMed: 24679532]
2. Flaño E, Husain SM, Sample JT, Woodland DL, Blackman MA. Latent Murine γ -Herpesvirus Infection Is Established in Activated B Cells, Dendritic Cells, and Macrophages. *J. Immunol*. 2000; 165:1074–1081. [PubMed: 10878386]
3. Goodwin MM, Canny S, Steed A, Virgin HW. Murine gammaherpesvirus 68 has evolved gamma interferon and stat1-repressible promoters for the lytic switch gene 50. *J. Virol*. 2010; 84:3711–3717. [PubMed: 20071569]
4. Steed A, Buch T, Waisman A, Virgin HW. Gamma interferon blocks gammaherpesvirus reactivation from latency in a cell type-specific manner. *J. Virol*. 2007; 81:6134–6140. [PubMed: 17360749]
5. Weck K, Kim S, Virgin H IV. Macrophages are the major reservoir of latent murine gammaherpesvirus 68 in peritoneal cells. *J. Virol*. 1999
6. Tibbetts SA, van Dyk LF, Speck SH, Virgin HW. Immune control of the number and reactivation phenotype of cells latently infected with a gammaherpesvirus. *J. Virol*. 2002; 76:7125–7132. [PubMed: 12072512]

7. Barton ES, et al. Herpesvirus latency confers symbiotic protection from bacterial infection. *Nature*. 2007; 447:326–329. [PubMed: 17507983]
8. Nguyen Y, McGuffie BA, Anderson VE, Weinberg JB. Gammaherpesvirus modulation of mouse adenovirus type 1 pathogenesis. *Virology*. 2008; 380:182–190. [PubMed: 18768196]
9. Saito F, et al. MHV68 Latency Modulates the Host Immune Response to Influenza A Virus. *Inflammation*. 2013; 36:1295–1303. [PubMed: 23807051]
10. Peacock JW, Elsawa SF, Petty CC, Hickey WF, Bost KL. Exacerbation of experimental autoimmune encephalomyelitis in rodents infected with murine gammaherpesvirus-68. *Eur. J. Immunol*. 2003; 33:1849–1858. [PubMed: 12811845]
11. Virgin HW, Wherry EJ, Ahmed R. Redefining chronic viral infection. *Cell*. 2009; 138:30–50. [PubMed: 19596234]
12. McSorley HJ, Hewitson JP, Maizels RM. Immunomodulation by helminth parasites: defining mechanisms and mediators. *Int. J. Parasitol*. 2013; 43:301–310. [PubMed: 23291463]
13. Salgame P, Yap GS, Gause WC. Effect of helminth-induced immunity on infections with microbial pathogens. *Nat. Immunol*. 2013; 14:1118–1126. [PubMed: 24145791]
14. Hwang S, et al. Persistent gammaherpesvirus replication and dynamic interaction with the host in vivo. *J. Virol*. 2008; 82:12498–12509. [PubMed: 18842717]
15. Moser JM, Upton JW, Allen RD, Wilson CB, Speck SH. Role of B-cell proliferation in the establishment of gammaherpesvirus latency. *J. Virol*. 2005; 79:9480–9491. [PubMed: 16014911]
16. Luche H, Weber O, Nageswara Rao T, Blum C, Fehling HJ. Faithful activation of an extra-bright red fluorescent protein in “knock-in” Cre-reporter mice ideally suited for lineage tracing studies. *Eur. J. Immunol*. 2007; 37:43–53. [PubMed: 17171761]
17. Reese TA, et al. Chitin induces accumulation in tissue of innate immune cells associated with allergy. *Nature*. 2007; 447:92–96. [PubMed: 17450126]
18. Loke P, et al. IL-4 dependent alternatively-activated macrophages have a distinctive in vivo gene expression phenotype. *BMC Immunol*. 2002; 3:7. [PubMed: 12098359]
19. Goodwin MM, et al. Histone deacetylases and the nuclear receptor corepressor regulate lytic-latent switch gene 50 in murine gammaherpesvirus 68-infected macrophages. *J. Virol*. 2010; 84:12039–12047. [PubMed: 20719946]
20. Gordon S, Martinez FO. Alternative Activation of Macrophages: Mechanism and Functions. *Immunity*. 2010; 32:593–604. [PubMed: 20510870]
21. Vats D, et al. Oxidative metabolism and PGC-1 β attenuate macrophage-mediated inflammation. *Cell Metab*. 2006; 4:13–24. [PubMed: 16814729]
22. Ohmori Y. Interleukin-4/STAT6 Represses STAT1 and NF-kappa B-dependent Transcription through Distinct Mechanisms. *Journal of Biological Chemistry*. 2000; 275:38095–38103. [PubMed: 10982806]
23. Gray KS, Allen RD, Farrell ML, Forrest JC, Speck SH. Alternatively initiated gene 50/RTA transcripts expressed during murine and human gammaherpesvirus reactivation from latency. *J. Virol*. 2009; 83:314–328. [PubMed: 18971285]
24. Wakeman BS, et al. Identification of alternative transcripts encoding the essential murine gammaherpesvirus lytic transactivator RTA. *J. Virol*. 2014
25. Harty JT, Schreiber RD, Bevan MJ. CD8 T cells can protect against an intracellular bacterium in an interferon gamma-independent fashion. *Proc Natl Acad Sci U S A*. 1992; 89:11612–11616. [PubMed: 1360672]
26. Jenkins SJ, et al. Local macrophage proliferation, rather than recruitment from the blood, is a signature of TH2 inflammation. *Science*. 2011; 332:1284–1288. [PubMed: 21566158]
27. Weck KE, Barkon ML, Yoo LI, Speck SH, HW IVV. Mature B cells are required for acute splenic infection, but not for establishment of latency, by murine gammaherpesvirus 68. *J. Virol*. 1996; 70:6775–6780. [PubMed: 8794315]
28. See supporting materials and methods in *Science* online.
29. Nakamura H, et al. Global changes in Kaposi's sarcoma-associated virus gene expression patterns following expression of a tetracycline-inducible Rta transactivator. *J. Virol*. 2003; 77:4205–4220. [PubMed: 12634378]

30. Wakeham K, et al. Parasite infection is associated with Kaposi's sarcoma associated herpesvirus (KSHV) in Ugandan women. *Infect. Agents Cancer*. 2011; 6:15. [PubMed: 21962023]
31. Kis LL, et al. STAT6 signaling pathway activated by the cytokines IL-4 and IL-13 induces expression of the Epstein-Barr virus-encoded protein LMP-1 in absence of EBNA-2: implications for the type II EBV latent gene expression in Hodgkin lymphoma. *Blood*. 2011; 117:165–174. [PubMed: 20876453]
32. Kaplan MH, Schindler U, Smiley ST, Grusby MJ. Stat6 is required for mediating responses to IL-4 and for development of Th2 cells. *Immunity*. 1996; 4:313–319. [PubMed: 8624821]
33. Odegaard JI, et al. Macrophage-specific PPARgamma controls alternative activation and improves insulin resistance. *Nature*. 2007; 447:1116–1120. [PubMed: 17515919]
34. Pesce JT, et al. Arginase-1-expressing macrophages suppress Th2 cytokine-driven inflammation and fibrosis. *PLoS Pathog*. 2009; 5:e1000371. [PubMed: 19360123]
35. Durbin JE, Hackenmiller R, Simon MC, Levy DE. Targeted disruption of the mouse Stat1 gene results in compromised innate immunity to viral disease. *Cell*. 1996; 84:443–450. [PubMed: 8608598]
36. Nair MG, et al. Alternatively activated macrophage-derived RELM- α is a negative regulator of type 2 inflammation in the lung. *J. Exp. Med*. 2009; 206:937–952. [PubMed: 19349464]
37. Warming S, Costantino N, Court DL, Jenkins NA, Copeland NG. Simple and highly efficient BAC recombineering using galK selection. *Nucleic Acids Res.e*. 2005; 33:e36.
38. Qian Z, Xuan B, Hong TT, Yu D. The full-length protein encoded by human cytomegalovirus gene UL117 is required for the proper maturation of viral replication compartments. *J. Virol*. 2008; 82:3452–3465. [PubMed: 18216115]
39. Adler H, Messerle M, Wagner M, Koszinowski UH. Cloning and mutagenesis of the murine gammaherpesvirus 68 genome as an infectious bacterial artificial chromosome. *J. Virol*. 2000; 74:6964–6974. [PubMed: 10888635]
40. Adler H, Messerle M, Koszinowski UH. Virus reconstituted from infectious bacterial artificial chromosome (BAC)-cloned murine gammaherpesvirus 68 acquires wild-type properties in vivo only after excision of BAC vector sequences. *J. Virol*. 2001; 75:5692–5696. [PubMed: 11356978]
41. Trapnell C, Pachter L, Salzberg SL. TopHat: discovering splice junctions with RNA-Seq. *Bioinformatics*. 2009; 25:1105–1111. [PubMed: 19289445]
42. Trapnell C, et al. Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation. *Nature Biotechnology*. 2010; 28:511–515.
43. Subramanian A, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. *Proc Natl Acad Sci U S A*. 2005; 102:15545–15550. [PubMed: 16199517]
44. Takeshita S, Kaji K, Kudo A. Identification and characterization of the new osteoclast progenitor with macrophage phenotypes being able to differentiate into mature osteoclasts. *J. Bone Miner. Res*. 2000; 15:1477–1488. [PubMed: 10934646]
45. Weck KE, et al. Murine γ -herpesvirus 68 causes severe large-vessel arteritis in mice lacking interferon- γ responsiveness: A new model for virus-induced vascular disease. *Nat Med*. 1997; 3:1346–1353. [PubMed: 9396604]
46. Tarakanova VL, Molleston JM, Goodwin M, Virgin HW IV, et al. MHV68 complement regulatory protein facilitates MHV68 replication in primary macrophages in a complement independent manner. *Virology*. 2010; 396:323–328. [PubMed: 19910013]
47. Goswami R, Kaplan MH. Gcn5 is required for PU.1-dependent IL-9 induction in Th9 cells. *J. Immunol*. 2012; 189:3026–3033. [PubMed: 22904310]
48. Renne R, et al. Lytic growth of Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) in culture. *Nat Med*. 1996; 2:342–346. [PubMed: 8612236]
49. Yoo SM, Zhou F-C, Ye F-C, Pan H-Y, Gao S-J. Early and sustained expression of latent and host modulating genes in coordinated transcriptional program of KSHV productive primary infection of human primary endothelial cells. *Virology*. 2005; 343:47–64. [PubMed: 16154170]
50. Lei X, et al. Regulation of NF-kappaB inhibitor IkappaBalpha and viral replication by a KSHV microRNA. *Nat. Cell Biol*. 2010; 12:193–199. [PubMed: 20081837]

51. Majerciak V, et al. Kaposi's sarcoma-associated herpesvirus ORF57 interacts with cellular RNA export cofactors RBM15 and OTT3 to promote expression of viral ORF59. *J. Virol.* 2011; 85:1528–1540. [PubMed: 21106733]
52. Persson LM, Wilson AC. Wide-scale use of Notch signaling factor CSL/RBP-Jkappa in RTA-mediated activation of Kaposi's sarcoma-associated herpesvirus lytic genes. *J. Virol.* 2010; 84:1334–1347. [PubMed: 19906914]
53. Ye F-C, et al. Kaposi's sarcoma-associated herpesvirus latent gene vFLIP inhibits viral lytic replication through NF-kappaB-mediated suppression of the AP-1 pathway: a novel mechanism of virus control of latency. *J. Virol.* 2008; 82:4235–4249. [PubMed: 18305042]




Fig. 1. Challenge with *H. polygyrus* and *S. mansoni* eggs reactivates MHV68

(A) C57BL/6J mice were infected intraperitoneally (i.p.) with MHV68-M3-FL and challenged with *H. polygyrus* 42 days later. Mice were imaged prior to *H. polygyrus* infection (day 0) and 5, 7 and 9 days after. Three representative mice imaged on days 0 and 7 are shown. (B) Total flux (photons/second) was quantitated for mice in 2 independent experiments for the timecourse after infection with *H. polygyrus*. Data from 4 independent experiments at day 7 post *H. polygyrus* is also shown. (C) C57BL/6J mice were infected intranasally (i.n.) with MHV68-M3-FL. Diagram indicates timecourse of experiment and challenge with *Sm* eggs or PBS as a control. Mice were injected with D-Luciferin and imaged prior to intravenous (i.v.) challenge with *Sm* eggs (day 0). They were subsequently imaged 5, 8 and 11 days after challenge with *Sm* eggs. Three representative mice imaged on days 0 and 8 are shown. (D) Total flux (photons/second) was quantitated from mice in two independent experiments after *Sm* egg challenge. Symbols represent individual mice, and the mean and standard error are indicated * p < 0.05, ** p < 0.01, *** p < 0.001 by 2-way repeated measures ANOVA with Tukey's and Bonferroni's post-test.




Fig. 2. IL-4 and IFN γ signatures identified in different macrophage populations during MHV68 infection

(A) GSEA analysis of virus-positive and virus-negative cells sorted from the peritoneum of MHV68-infected mice compared to BMDMs stimulated with IL-4 or IFN γ /LPS. (B) C57BL/6J mice or YARG/R26-stop-RFP mice were either mock infected or infected with MHV68-cre. CD11b+F4/80+ cells were gated and examined for RFP and YFP expression. Representative plots from two independent experiments, with three to five mice per experiment. (C) Quantitation of FACS analysis in (B) with each symbol representing a single mouse.




Fig. 3. IL-4 promotes viral replication and antagonizes IFN γ suppression of viral replication through direct binding to a viral promoter

(A) BMDMs were untreated or treated with the indicated doses of IL-4 and infected with MHV68. 24 hours post infection cells were analyzed for expression of MHV68 lytic viral proteins and CD206 expression. Represents three independent experiments. (B) Pretreatment of BMDMs with IL-4, IL-13, or IL-5 prior to infection with MHV68 and FACS analysis. (C) BMDMs were pretreated with varying doses of IFN γ \pm 10 ng/ml of IL-4. 24 hours post infection cells were analyzed for expression of lytic viral proteins. Represents three independent experiments. (D) *Gene 50* expression was analyzed by RT-PCR in BMDMs pretreated with IL-4 and/or IFN γ . Expression was normalized to *Gapdh*. Represents four independent experiments. (E) RAW264.7 cells were transfected with vectors expressing luciferase under control of four different *gene 50* promoters ((23, 24). Cells were then treated \pm IL-4 or IL-13 for 24 hours, lysed and assayed for luciferase activity. (F) Cells were transfected with the N4/N5 promoter luciferase construct and treated with IL-4, IFN γ , or both. (G) N4/N5 luciferase mutants were transfected into RAW264.7 cells and assayed for sensitivity to IL-4. (H) RAW264.7 cells were infected with MHV68 at MOI=5 and treated

with IL-4 for 8 hours. After chromatin immunoprecipitation with Stat6 antibody, quantitative PCR was performed for the N4/N5 promoter region or VEGF. Percent of input after normalizing to IgG control was calculated for both N4/N5 and VEGF. 1 experiment representative of 4 independent experiments is shown. **(I)** Schematic of N4/N5 luciferase construct with potential Stat-binding mutants. n.d. not detected. n.s. not significant. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, **** $p < 0.0001$ by T test or 1-way ANOVA with Sidak's multiple comparisons test.




Fig. 4. MHV68 and KSHV reactivation from latency is regulated by IL-4

(A) C57BL/6/J mice were infected with MHV68-M3-FL i.p. 42 days later mice were imaged for luciferase expression (d0) and then received isotype control (PIP), anti-IFN γ (H22), IL4c, or both anti-IFN γ and IL-4c. On day 44 mice received a second dose of IL4c or PBS. Mice were imaged five days after the first treatment and total flux from the abdominal region was quantitated. Four representative mice are shown. (B) Quantitation of total flux from three individual experiments described in (A) are shown. Each symbol represents an individual mouse. Bars are means, and error bars are standard errors. (C) WT or Stat6KO

mice were treated as in (A) with anti-IFN γ /IL4c and imaged 5 days later. Bars are the means of individual mice (symbols), and error bars are standard error. **(D)** Experimental set-up was the same as Fig. 1A. Latently infected WT and Stat6KO mice infected with MHV68-M3-FL were infected with *H. polygyrus* or treated with PBS on day 42 and reactivation was quantitated by luciferase induction 7 days later. **(E)** BCBL-1 cells were treated with IL-4 for 3 or 5 days or TPA for 48 hours and viral gene expression was analyzed. Shown is the fold increase in gene expression over mock after normalization of GAPDH. Data from 3 independent experiments. **(F)** Supernatants from cells treated in (E) were collected and virus was isolated by centrifugation. Viral genome copy number was assayed by qPCR using serial diluted LANA expression plasmid as a standard curve. 1 experiment representative of 2 independent experiments is shown. For luciferase experiments: * $p < 0.05$, ** $p < 0.01$, n.s. not significant by 2-way repeated measures ANOVA with Tukey's and Bonferroni's post-test.